Biotech company DAB has raised a considerable amount of pre-series A funding. The new investment allows the spin-off from TU Delft to invest in its first FAST demonstration bioreactor, and further develop its technology and product pipeline.
DAB is the leading expert in separation technology of oil-based fermentation. The FAST technology reduces product costs with 20-50+ percent and promises to enable commercial production of many bio-based compounds, replacing their fossil-based equivalents.
The new FAST unit will be placed at a reputable contract research and manufacturing organisation, where it will be coupled with a ~10 m3 conventional fermenter, to multiply the fermenter’s production capacity. The system will serve to run demonstrations, produce initial samples and run commercial production of high value compounds.
With this investment, the development of the FAST technology has reached an important milestone – readiness for small-scale commercial productions – and is ready for wide-scale deployment. DAB is working with a range of partners to develop a pipeline of demonstration and commercial runs.
Biotech Campus Delft
DAB is located on the Biotech Campus Delft. The funding, at undisclosed terms, is provided by DAB’s existing shareholders.